AstraZeneca预测在癌症药物、美国和中国投资的推动下,2026年增长强劲, AstraZeneca forecasts strong 2026 growth fueled by cancer drugs, U.S. and China investments, and a 3% dividend hike.

阿斯利康预计2026年收入将实现中高个位数增长，核心盈利将实现低两位数增长，这得益于强劲的抗癌药物销售、强劲的供应链以及对美中战略投资的推动。 AstraZeneca projects mid-to-high single-digit revenue growth and low double-digit core earnings growth for 2026, driven by strong cancer drug sales, a robust pipeline, and strategic investments in the U.S. and China. 该公司报告说,2025年第四季度的收入达155亿美元,达到了预期,核心收入为每股2.12美元。 The company reported fourth-quarter 2025 revenue of $15.5 billion, meeting expectations, with core earnings of $2.12 per share. 癌症药物销售额增长20%,达到70.3亿美元,心血管疾病收入由于非专利药物而下降6%。 Cancer drug sales rose 20% to $7.03 billion, while cardiovascular revenue fell 6% due to generics. AstraZeneca将其红利提高了3%,并通过美国500亿美元的制造业交易、纽约证券交易所的上市和在白宫定价协议支持下在中国投资150亿美元,继续扩张。 AstraZeneca raised its dividend by 3% and continues expanding through a $50 billion U.S. manufacturing deal, an NYSE listing, and a $15 billion investment in China, supported by a White House pricing agreement.